Pot stocks fall as US DEA pushes cannabis reclassification hearing to December
Aug 27 (Reuters) -Shares of cannabis companies sank on Tuesday after the U.S. Drug Enforcement Administration (DEA) postponed its cannabis reclassification hearing to Dec. 2, after the U.S. presidential election.
The Department of Justice, which oversees the DEA, said Attorney General Merrick Garland recommended cannabis be reclassified as a Schedule three drug instead of Schedule one earlier this year. Schedule one is reserved for drugs with a high potential for abuse and no accepted medical use.
Shares of Curaleaf CURA.TO and U.S.-listed shares of Canopy Growth CGC.O fell over 10%, while Illinois-based Verano Holdings VRNO.NLB was down 12.9%.
The AdvisorShares Pure US Cannabis ETF dipped 9.1%, having fallen as much as 12% earlier in the session.
Canada-listed Green Thumb Industries GTII.CD, Tilray Brands TLRY.TO, and Trulieve Cannabis TRUL.CD were down 8.6%, 6% and 5% respectively.
"We believe both candidates are likely to let rescheduling advance, though we have more confidence in Kamala Harris than in Donald Trump," said analysts at TD Cowen in a note.
Analysts also noted that the outcome would heavily depend on Trump's choice for key positions such as Attorney General, the director of the DEA, and the Secretary of Health and Human Services, should he win.
The HHS' National Survey on Drug Use and Health for 2023 showed that marijuana is the most commonly used illicit drug, with 21.8% of people aged 12 or older, or 61.8 million people, reporting use.
Reclassifying marijuana would represent a first step toward narrowing the wide policy chasm between state and federal cannabis laws.
Medical cannabis is legal in 38 states and various U.S. territories, while recreational use is permitted in 24 states and Washington, D.C.; however, it remains federally illegal.
Until then, "the extended wait for rescheduling decisions could maintain the status quo, leaving businesses to navigate a patchwork of state regulations and ongoing federal ambiguity," said Pete Sahani chief executive officer of the cannabis hardware firm, the Blinc Group.
Reporting by Seher Dareen in Bengaluru; Editing by Tasim Zahid
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
